PPARG and pancreatic neoplasm: TZD has also been demonstrated to inhibit pancreatic cancer cell invasiveness, a process that affects gelatinolytic and fibrinolytic activity with a mechanism independent of PPAR-γ activation, which involves matrix metalloproteinase 2 and plasminogen activator inhibitor 1 expression (22).